SC
EXAS

Sophrosyne Capital’s Exact Sciences EXAS Stock Holding History

Sophrosyne Capital’s Portfolio EXAS Stock Details EXAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-31,700
Closed -$540K – 66
2014
Q2 		$540K Buy
+31,700
New +$436K 0.55% 36

Other funds holding EXAS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Sophrosyne Capital's EXAS Position: Q3 2014 in Review

Sophrosyne Capital sold out of Exact Sciences (EXAS) in Q3 2014, closing a stake of 31,700 shares — an estimated $540K sold.

Sophrosyne Capital first reported a position in EXAS in Q2 2014 and held it in 1 quarter. The position peaked at $540K in Q2 2014. 175 funds tracked by Wall St. Rank hold EXAS as of Q3 2014.

  • Sophrosyne Capital reported no remaining Exact Sciences position as of Q3 2014 after selling out during the quarter.
  • Sophrosyne Capital sold 31,700 Exact Sciences shares in Q3 2014, an estimated $540K.
  • Sophrosyne Capital first reported a position in Exact Sciences in Q2 2014 and held it in 1 quarter.
  • Sophrosyne Capital's Exact Sciences position peaked at $540K in Q2 2014.
  • 175 funds tracked by Wall St. Rank held Exact Sciences as of Q3 2014.

Based on Sophrosyne Capital's 13F filing for Q3 2014, filed 14 Nov 2014.